-transparent.png){kind=logo}
Idarubicin (4-demethoxydaunorubicin) is an orally active anthracycline. We treated 26 patients with 37 courses of the drug on a schedule of oral administration weekly x 3 followed by a 3-week rest period. The maximum tolerated dose on this schedule was 22.5 mg/m2 weekly x 3 every 6 weeks, with consistent myelosuppression being the dose-limiting toxicity; other toxicity was minimal. Pharmacologic studies showed a mean alpha half-life of 1.6 +/- 0.3 h and a beta half-life of 39 +/- 8.4 h for idarubicin. This schedule was well tolerated, with consistent toxicity patterns seen. Pharmacologic studies confirmed prolonged exposure to the drug and its active metabolite. In comparison with other schedules, this one may offer advantages in terms of consistent hematologic toxicity and prolonged exposure to both the parent compound and its active metabolite. Dose intensity was comparable with that on other schedules.
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
January 1984,
Investigational new drugs,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
January 1988,
Cancer chemotherapy and pharmacology,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
January 1986,
Investigational new drugs,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
January 1984,
Investigational new drugs,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
April 1988,
European journal of cancer & clinical oncology,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
June 1987,
Cancer research,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
April 1987,
European journal of cancer & clinical oncology,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
August 1986,
Onkologie,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
January 1983,
Investigational new drugs,
H Hochster, and
M Green, and
L Liebes, and
J L Speyer, and
J Wernz, and
R Blum, and
F Muggia
July 1986,
Cancer treatment reports,
